About This Webinar
As expectations for robust, real-world evidence continue to grow, understanding how regulators evaluate causal analyses is becoming increasingly important.
In this session, we will explore why causality matters, how agencies such as the FDA, EMA, and NICE are viewing causal inference, and what this means for study design and regulatory submissions.
Speakers include:
- Ryan Batten, Senior Statistician
- Julien Tanniou, Ph.D., Expert Statistical Methodologist, Saryga
Key topics will include:
- The role of causal inference in regulatory decision-making
- Methods currently used and accepted by regulators
- Practical approaches such as Directed Acyclic Graphs (DAGs) and target trial emulation
This webinar is designed for statisticians, programmers, and researchers working with real-world data, epidemiology, and clinical trials, particularly those involved in regulatory submissions.
Whether you are designing a study or preparing evidence for submission, this session will provide practical insights into applying causal methods in a regulatory context.
